These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9382447)

  • 21. [Chemotherapy-induced cardiac toxicity and management].
    Komagata H; Sakai H
    Gan To Kagaku Ryoho; 2003 Jun; 30(6):787-92. PubMed ID: 12852345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug may protect children's hearts from chemotherapy.
    McBride D
    ONS Connect; 2010 Dec; 25(12):15. PubMed ID: 21214085
    [No Abstract]   [Full Text] [Related]  

  • 23. Extravasation: a dreaded complication of chemotherapy.
    Schrijvers DL
    Ann Oncol; 2003; 14 Suppl 3():iii26-30. PubMed ID: 12821535
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
    Gershanovich ML
    Vopr Onkol; 2001; 47(1):119-22. PubMed ID: 11317530
    [No Abstract]   [Full Text] [Related]  

  • 25. Different anthracycline derivates for reducing cardiotoxicity in cancer patients.
    van Dalen EC; Michiels EM; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005006. PubMed ID: 17054231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiotoxicity of conservative treatment of solid tumors].
    Sivak LA; Askol'skiĭ AV; Lial'kin SA; Klimanov MIu; Maĭdanevich NN; Kasap NV
    Lik Sprava; 2011; (3-4):51-9. PubMed ID: 22416364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthracycline antibiotics induce acute renal tubular toxicity in children with cancer.
    Bárdi E; Bobok I; V Oláh A; Kappelmayer J; Kiss C
    Pathol Oncol Res; 2007; 13(3):249-53. PubMed ID: 17922055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anthracycline cardiotoxicity debate.
    Barber G
    Pediatrics; 1994 Nov; 94(5):778; author reply 781-2. PubMed ID: 7936922
    [No Abstract]   [Full Text] [Related]  

  • 30. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
    Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
    J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Doxorubicin-induced cardiomyopathy.
    Swain SM
    N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cardioxan: prevention of anthracycline-related cardiotoxicity].
    Gershanovich ML
    Vopr Onkol; 2004; 50(4):482-91. PubMed ID: 15605776
    [No Abstract]   [Full Text] [Related]  

  • 33. The anthracycline cardiotoxicity debate.
    Finlay J; Meadows AT
    Pediatrics; 1994 Nov; 94(5):780-1; author reply 781-2. PubMed ID: 7936925
    [No Abstract]   [Full Text] [Related]  

  • 34. [Evaluation of the cardioprotective effect of bispiperazinedione ICRF-187 (Cardioxane) in patients treated with anthracyclines--an echocardiographic study].
    Elbl L; Vásová I; Chaloupka V; Hájek R; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):268-73. PubMed ID: 8693714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anthracycline cardiotoxicity debate.
    Friedman DM
    Pediatrics; 1994 Nov; 94(5):778-9; author reply 781-2. PubMed ID: 7936923
    [No Abstract]   [Full Text] [Related]  

  • 36. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
    Silber JH
    Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
    [No Abstract]   [Full Text] [Related]  

  • 37. Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracycline-induced cardiotoxicity (review).
    Orditura M; Quaglia F; Morgillo F; Martinelli E; Lieto E; De Rosa G; Comunale D; Diadema MR; Ciardiello F; Catalano G; De Vita F
    Oncol Rep; 2004 Sep; 12(3):549-56. PubMed ID: 15289836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review.
    Swain SM; Vici P
    J Cancer Res Clin Oncol; 2004 Jan; 130(1):1-7. PubMed ID: 14564513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The use of Cardioxane in chemotherapy of malignant neoplasms in children].
    Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA
    Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results.
    Schiavetti A; Castello MA; Versacci P; Varrasso G; Padula A; Ventriglia F; Werner B; Colloridi V
    Pediatr Hematol Oncol; 1997; 14(3):213-22. PubMed ID: 9185206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.